Empagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study - PubMed
4 hours ago
- #SGLT2 inhibitors
- #renal outcomes
- #chronic kidney disease
- The study compares empagliflozin and dapagliflozin in stage 3 chronic kidney disease (CKD) patients.
- Empagliflozin showed a lower risk of progression to stage 5 CKD or end-stage kidney disease (ESKD) compared to dapagliflozin (HR: 0.84; 95% CI: 0.79-0.89).
- All-cause mortality was similar between the two groups.
- The findings suggest empagliflozin may be more effective in delaying kidney disease progression in stage 3 CKD.